Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers FDA Decision: Guardant Health (GH)

The Phase 2 date for Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers by Guardant Health (GH) is scheduled for May 1, 2026. This is the target date for the FDA to make a decision on this application.

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers is being developed by Guardant Health for the treatment of its target indication. It is currently in Phase 2 clinical trials.

If Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers receives FDA approval, Guardant Health (GH) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 2 date closely.

Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for GH on DilutionWatch at dilutionwatch.com/stock/GH.html.

You can view the full BiotechSigns company profile for Guardant Health (GH) at biotechsign.com/app/company/GH, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.